ALK and non-small cell lung carcinoma: In conclusion, this is the first report of a NSCLC patient with STRN‐ALK rearrangement exhibiting primary resistance to alectinib; in addition, limited clinical activity of crizotinib in the alectinib‐resistant setting was observed.